Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Giorgio BolisF Parazzini

Abstract

To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial. Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment. A total of 64 women were allocated to epidoxorubicin and 74 to no treatment. There were 20 and 19 deaths, respectively, in the epidoxorubicin and no-treatment groups. The 3-year percent overall survival was 79.0% and 78.7%, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P= 0.93).

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Oct 19, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B VermorkenG Bolis
Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P F ConteC Cianci
Jun 13, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B Sorbe, UNKNOWN Swedish-Norgewian Ovarian Cancer Study Group
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mahesh A VariaUNKNOWN Gynecologic Oncology Group
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M J PiccartJ B Vermorken
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S PecorelliG Favalli
Sep 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan S BerekChristopher F Nicodemus

❮ Previous
Next ❯

Citations

May 29, 2012·Medical Oncology·Achuta Kumar Guddati
Nov 3, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·F C Muñoz-CasaresA Gómez-Portilla
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Bookman
May 18, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A H Comander, S A Cannistra
Apr 11, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A Bookman
May 1, 2010·Therapeutic Advances in Medical Oncology·Mihaela CristeaRobert J Morgan
Nov 10, 2012·Critical Reviews in Oncology/hematology·Bradley J MonkIvor Benjamin
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael A Bookman
Jan 9, 2010·Gynecologic Oncology·Valentina GuarneriPier Franco Conte
Sep 1, 2009·Gynecologic Oncology·Talia FosterThomas J Herzog
Dec 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Michael A Bookman
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul J Hoskins
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineAndreas du Bois
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sergio PecorelliUNKNOWN After 6 Italian Cooperative Group
May 9, 2013·Journal of Gynecologic Oncology·Michael A Bookman
Jun 11, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Angiolo GadducciUNKNOWN Members of the After-6 Italian Cooperative Group
Jan 9, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Michael A Bookman
Jun 24, 2014·Expert Review of Anticancer Therapy·Cristina FalciPierfranco Conte
Jul 3, 2013·The Cochrane Database of Systematic Reviews·Ling MeiDan Feng
Jan 9, 2015·Cancer Metastasis Reviews·Maurie Markman
Feb 22, 2012·Clinical Obstetrics and Gynecology·Michael A Bookman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

© 2021 Meta ULC. All rights reserved